KRAS and cancer: Thus, KRAS-TP53 co-mutated (KP) cancers are those that demonstrated the best response to immunotherapy (98) having high TMB, high expression of PD-L1 that seems to depend on extracellular signal-regulated kinases (ERK) signaling (99) and high T cell infiltration (100, 101).